Highlights ImpediMed Limited

Equities

IPD

AU000000IPD8

Market Closed - Australian S.E. Other stock markets 02:10:46 2024-06-13 am EDT			5-day change	1st Jan Change
0.065 ^AUD	-2.99%		-8.45%	-55.17%

Jun. 07	ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director	CI
Apr. 30	ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8%	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8%	Apr. 29	MT
Impedimed Implements Organizational Changes; Makes Strategy Chief, COO Redundant	Apr. 16	MT
ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting	Apr. 11	CI
ImpediMed Narrows Loss in Fiscal H1, Revenue Declines; Shares Fall 7%	Feb. 26	MT
ImpediMed Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 26	CI
ImpediMed Secures Payor Clearance for Spectroscopy Device in the US; Shares Rise 4%	Nov. 02	MT
Impedimed Widens Fiscal 2023 Loss; Shares Down 3%	23-08-31	MT
ImpediMed Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Impedimed's Bioimpedance Spectroscopy Platform Gets Boost Following US Cancer Network Guideline Update	23-03-27	MT
ImpediMed Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival	22-12-15	CI
ImpediMed Extends Contract for AstraZeneca for Use of the SOZO Digital Health Platform in Clinical Trial of Patients with Chronic Kidney Disease	22-11-16	CI
ImpediMed Secures Contract Extension for Use of Device in Clinical Trial	22-11-09	MT
Impedimed Limited Announces Third Contract Extension Related to the Use of the SOZO Digital Health Platform in A Clinical Trial Being Conducted for AstraZeneca	22-11-08	CI
ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema	22-10-26	CI
ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer	22-10-11	CI
ImpediMed Partners with GenesisCare for US Launch of Lymphedema Prevention Program	22-10-05	MT
ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients	22-10-04	CI
Impedimed Limited Announces the Signing of Global Strategic Commercial Partnership and Pilot Program with Genesiscare	22-10-03	CI
ImpediMed Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ImpediMed Limited

Equities

IPD

AU000000IPD8

Highlights

Filters